Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.39 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148926 | 0.82 | MEN1 (0.49) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL10292998 | 0.79 | KMT2A (0.53) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL20714808 | 0.79 | KMT2A (0.46) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL4565550 | 0.79 | MEN1 (0.46) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL25360643 | 0.76 | MEN1 (0.43) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL8763365 | 0.75 | MEN1 (0.49) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL27993985 | 0.75 | MEN1 (0.56) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL29874131 | 0.74 | MEN1 (0.60) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL3625928 | 0.74 | MEN1 (0.60) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 | |
| SCHEMBL29250332 | 0.74 | SLC22A12 (0.52) | MEN1KMT2ASLC22A12HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| CN-102405211-A | Proline derivatives as cathepsin inhibitors | HOFFMANN LA ROCHE | 2012-04-04 | — | — | CN | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| EP-1963317-A1 | USE OF PYRROLO [2 , 3-B]PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | MEN1 2996/4885KMT2A 3959/4885SLC22A12 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.